Luigi Fattore
Link Campus University · 71 works · 1,330 citations · h-index 24
Top works
- miR-579-3p controls melanoma progression and resistance to target therapy
- MicroRNAs in melanoma development and resistance to target therapy
- Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
- Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
- Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
- Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
- Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
- TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
- Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
- Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR)
- CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions
- Selective targeting of point-mutated KRAS through artificial microRNAs
- Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells
- ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
- MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma
- microRNA-378a-5p iS a novel positive regulator of melanoma progression
- Melanoma and immunotherapy bridge 2015
- Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance